An interventional study of [68Ga]Ga-PentixaFor PET/CT in Metastatic Breast Cancer, sponsored by Institut Cancerologie de l'Ouest. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-12.
Sponsored by Institut Cancerologie de l'Ouest · Not applicable, Interventional, and Diagnostic
Triple-negative breast cancer (TNBC) is a particularly aggressive type of breast cancer that is difficult to treat. Unlike other forms of breast cancer, TNBC tends to relapse earlier and spread more quickly to other parts of the body. Unfortunately, patients with TNBC have a lower survival rate, often less than five years after diagnosis. This highlights the urgent need for better treatments for TNBC.
One of the main challenges in treating TNBC is that it lacks certain receptors that other breast cancers have. These receptors are usually targeted by specific therapies, making TNBC harder to treat with targeted approaches.
Currently, a type of imaging called [18F]FDG PET/CT is the most accurate method for detecting breast cancer and its spread. However, with the rise of personalized medicine, there is a growing interest in molecular targeted approaches. These methods aim to provide highly specific diagnostics and treatments based on the unique characteristics of each patient's cancer.
One promising target for these new approaches is a receptor called CXCR4. CXCR4 is found on the surface of many cells and is involved in various processes in the body. It is often overexpressed in different types of cancer, including breast cancer. Research has shown that CXCR4 levels are higher in metastatic sites (where cancer has spread) compared to primary tumors. CXCR4 is not only present in cancer cells but also in immune cells within the tumor environment.
In invasive breast cancer, CXCR4 plays a crucial role in tumor migration, invasiveness, metastasis, and proliferation. A clinical study evaluated 18 breast cancer patients using a new imaging method called [68Ga]Ga-PentixaFor PET/CT or PET/MR. They found that this method showed higher uptake in breast cancer cases with poorer prognosis compared to the traditional [18F]FDG PET/CT. Higher CXCR4 expression is particularly seen in TNBC compared to other breast cancer subtypes.
The goal of the study is to assess how [68Ga]Ga-PentixaFor is distributed in the body using PET/CT imaging. This will help demonstrate the potential of CXCR4 as a promising target for new treatments. If successful, [68Ga]Ga-PentixaFor PET/CT could become a valuable tool for identifying patients who might benefit from treatments using [177Lu]/[90Y] PentixaTher.
Triple-negative breast cancer (TNBC) is the most aggressive and hard-to-treat form of breast cancer. TNBC has a higher propensity for earlier relapse and an increased risk of metastasis than all other forms of breast cancer. TNBC patients have a low survival rate (\<5 years). This clearly shows an urgent unmet medical need for TNBC patients. The lack of receptors makes it challenging to develop more effective targeted therapy to treat TNBC.
Currently, [18F]FDG PET/CT offer highest diagnostic accuracy in the detection of breast cancer and distant metastases. With the increasing role of personalized medicine, however, the desire for molecular targeted approaches emerged, enabling high-specificity diagnostics and molecular targeted therapies with the appropriate molecular key target.
CXCR4 is a 7-transmembrane G-coupled receptor belonging to the chemokine receptor family and is expressed by a variety of cells during development and thereafter. CXCR4 has been found to be overexpressed by various human cancers including breast cancer. The level of CXCR4 expression was shown to be higher in metastatic sites as compared to the primary tumours, and changes in CXCR4 signalling have been shown to significantly alter metastatic burden in animal models. CXCR4 is not only expressed by cancer cells themselves, but also by tumour-infiltrating immune cells. Within the tumour microenvironment, the major CXCR4-expressing cells are B-lymphocytes and plasmacytoid dendritic cells, both potentially contributing to an immunosuppressive site permissive for tumour progression.
CXCR4 is frequently overexpressed in invasive breast cancer and has an important role in tumour migration, invasiveness, metastasis, and proliferation (2).
Vag et al. evaluated 18 patients with breast cancer who underwent [68Ga]Ga-PentixaFor PET/CT or PET/MR (6). It was noted that a higher SUVmax of [18F]FDG was observed in all cases, compared with [68Ga]Ga-PentixaFor. It was also noted that the uptake seen in breast cancer is associated with a poorer prognosis. Higher CXCR4 expression is seen in triple-negative breast cancer compared to the luminal subtypes. [68Ga]Ga-PentixaFor PET/CT may have a role in prognostication of breast cancer.
The purpose of this trial is to assess the biodistribution of [68Ga]Ga-PentixaFor using PET/CT imaging, thus allowing us to demonstrate the potential of CXCR4 as a promising molecular target.
After establishing the targeting properties of [68Ga]Ga-PentixaFor PET/CT in TNBC, it could act as an effective companion imaging diagnostic and therefore a useful tool for identification of patients potentially benefiting from treatment using the theragnostic equivalent [177Lu]/[90Y] PentixaTher.
12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.
This study's planned enrollment of 12 is below the median of 72 across 9,303 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Institut Cancerologie de l'Ouest is the lead sponsor of 105 studies on the registry; 18 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Primitive triple negative breast cancer proven histologically, defined according to the following criteria:
Adequate Organ function confirmed by laboratory tests results allowing for safe administration of [68Ga]Ga- PentixaFor:
Hematologic function: Absolute Neutrophil Count (ANC) of ≥ 1.5 x 109 /L, platelet count of ≥ 100 x 109 /L, and hemoglobin of ≥ 9 g/dL).
Hepatic function: AST and ALT ≤ 3 x ULN (≤ 5 x ULN if liver metastases).
Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
Exclusion Criteria:
2 \[68Ga\]Ga-PentixaFor PET-CT are performed after patient inclusion and at disease progression.
Diagnostic Test: [68Ga]Ga-PentixaFor PET/CT
\[68Ga\]Ga-PentixaFor PET-CT is performed after patient inclusion. The patient is treated as per standard of care until disease progression. Then another \[68Ga\]Ga-PentixaFor PET-CT is performed.
To assess the concordance for tumour lesion detection with [68Ga]Ga-PentixaFor PET/CT and [18F]FDG PET/CT based on a lesion-by-lesion basis analysis performed at patient inclusion
Concordance study of metastatic uptake seen in \[18F\]FDG PET/CT scan and \[68Ga\]Ga-PentixaFor PET/CT scan per "lesion" by comparing for each lesion the \[18F\]FDG PET scan and \[68Ga\]Ga-PentixaFor PET/CT scan by assessing a ratio "Number of positive or negative \[68Ga\]Ga-PentixaFor lesions / Number of positive or negative FDG lesions" performed at patient inclusion
Time frame: 1 day
To assess the concordance for tumour lesion detection with [68Ga]Ga-PentixaFor PET/CT and [18F]FDG PET/CT based on a lesion-by-lesion basis analysis performed at disease progression
Concordance study of metastatic uptake seen in \[18F\]FDG PET/CT scan and \[68Ga\]Ga-PentixaFor PET/CT scan per "lesion" by comparing for each lesion the \[18F\]FDG PET/CT scan and \[68Ga\]Ga-PentixaFor PET/CT scan by assessing a ratio "Number of positive or negative \[68Ga\]Ga-PentixaFor lesions / Number of positive or negative FDG lesions" performed at disease progression
Time frame: 36 months
To assess the concordance for tumour lesion detection with [68Ga]Ga-PentixaFor PET/CT and conventional imaging CT scan based on a lesion-by-lesion basis analysis performed at patient inclusion
Conventional imaging (CT scan), and \[68Ga\]Ga-PentixaFor PET/CT will be analysed for each lesion, obtaining a ratio of number of \[68Ga\]Ga-PentixaFor(+) lesions / number of CT scan lesions" at patient inclusion
Time frame: 1 day
To assess the concordance for tumour lesion detection with [68Ga]Ga-PentixaFor PET/CT and conventional imaging: CT scan based on a lesion-by-lesion basis analysis performed at disease progression
Conventional imaging: CT scan, and \[68Ga\]Ga-PentixaFor PET/CT will be analysed for each lesion, obtaining a ratio of number of \[68Ga\]Ga-PentixaFor(+) lesions / number of CT scan lesions" at disease progression
Time frame: 36 months
To determine the percentage of total tumour burden (whole body) detected on [68Ga]Ga-PentixaFor PET/CT compared to that defined on [18F]FDG PET/CT (considered as reference).
Percentage of \[68Ga\]Ga-PentixaFor(+) metastatic tumour burden compared to total metastatic tumour burden by \[18F\]FDG PET/CT
Time frame: 36 months
To assess the correlation between the standard uptake values (SUV) of [68Ga]Ga-PentixaFor and CXCR4 expression by IHC assessment on primitive and/or metastatic tumour samples at screening and at disease progression if a biopsy is performed
Assess the correlation between the standard uptake values (SUV) of \[68Ga\]Ga-PentixaFor and IHC CXCR4 expression, by comparing the \[68Ga\]Ga-PentixaFor semi-quantitative data with the CXCR4 expression results of biopsied metastases at screening and at disease progression if biopsy is performed
Time frame: 36 months
To assess the safety and tolerance of [68Ga]Ga-PentixaFor
The tolerance of \[68Ga\]Ga-PentixaFor will be checked by measuring and monitoring vital signs for 60 minutes after \[68Ga\]Ga-PentixaFor administration. The patient will be informed that in the event of abnormal physical signs, occurring within 48 hours after \[68Ga\]Ga-PentixaFor administration, he (she) must inform the investigator for registration. The CTC-NCI Common Toxicity Criteria, version 5.0 reference will be used
Time frame: 2 days
To assess the prognostic value of serum FLT3-Ligand in relapsing Triple Negative Breast Cancer patients
Plasma FLT3-Ligand dosage will be performed at screening, every 3 months during treatment period and at disease progression follow-up visit for all patients. The relationship between FLT3-Ligand levels and patient outcomes (OS and DFS) will be analysed using Kaplan-Meier survival analysis and univariable Cox analysis
Time frame: 36 months
Plan to share: No — The IPD data is confidential.
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut Cancerologie de l'Ouest